AMRX - Amneal Pharmaceuticals Inc

NYSE * Health Care * Pharmaceuticals

$12.43

$-0.11 (-0.88%)

About Amneal Pharmaceuticals Inc

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

AMRX Key Statistics

Market Cap

$4.00B

P/E Ratio

57.00

P/B Ratio

105.45

EPS

$0.22

Revenue Growth

+0.1%

Profit Margin

0.0%

Employees

8,700

How AMRX Compares to Peers

AMRX trades at a premium valuation vs peers (highest P/E)
AMRX is the smallest among peers, which may offer higher growth potential

P/E Rank

#2

of 2

Margin Rank

#2

of 2

Growth Rank

#2

of 2

Size Rank

#2

of 2

CompanyP/EGrowthCompare
AMRX57.00%-
AMZN33.40%vs AMZN

Amneal Pharmaceuticals Inc Company Information

Headquarters
nan
Website
www.amneal.com
Sector
Health Care
Industry
Pharmaceuticals
Data Updated:
Ready to invest in AMRX?

Commission-free trading available. Affiliate links.

AMRX Lician Score

10% confidence
6.0/10
Good

AMRX has a Lician Score of 6/10 (Good). Strengths: Growth.

value

5.0

growth

8.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates AMRXacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

AMRX Financial Snowflake

5-axis analysis across key investment dimensions

5.6/10

Neutral

35810Value5.0Growth8.0Quality5.0Momentum5.0Safety5.05.6/10
5.0

Value

8.0

Growth

5.0

Quality

5.0

Momentum

5.0

Safety

Upcoming Events for AMRX